Physiology of the Proton Pump and Drug Target
Gastric hydrochloric acid secretion is driven by a specialized enzyme, the $H^+/K^+$-ATPase, located in the membrane of parietal (oxyntic) cells. The primary function of this pump is to exchange intracellular hydrogen ions for extracellular potassium ions.
Enzyme activity is tightly regulated by mediator signals from three major receptor types:
- Histamine receptors;
- Gastrin receptors;
- Acetylcholine receptors.
Proton pump inhibitors block this process more effectively than any other antisecretory agents, and this inhibition is irreversible. Recovery of acid secretion becomes possible only after de novo synthesis of new enzyme molecules.
Pharmacology of Omeprazole
Omeprazole, a chemical derivative of benzimidazole, serves as the prototype representative of this group. Its mechanism of action involves the irreversible inhibition of the $H^+/K^+$-ATPase of gastric parietal cells.
Clinical efficacy is exceptionally high: a single dose can suppress gastric acid secretion by over 90% for 24 hours. However, adverse reactions may occur, such as dyspeptic symptoms (including nausea) and headache.
An important pharmacokinetic feature of omeprazole is its ability to interact with the cytochrome P450 system, significantly increasing the risk of clinically relevant drug-drug interactions.
Risks of Long-Term Therapy and the Rebound Mechanism
Prolonged, uncontrolled use of proton pump inhibitors is associated with significant limitations and patient risks. The primary danger lies in the development of the "rebound" mechanism:
- Achlorhydria develops—a complete absence of free hydrochloric acid in the stomach.
- The body responds with a compensatory increase in gastrin secretion.
- Excess gastrin stimulates enterochromaffin-like (ECL) cell and parietal cell hyperplasia, observed in 10–20% of patients.
For this reason, these drugs are prescribed strictly according to indications—for acute peptic ulcer disease in short courses lasting no more than 4–8 weeks. Additionally, there is a risk of gastric mucosal atrophy.
Other Agents and Combination Therapy
In addition to omeprazole, other drugs in this class used in clinical practice include lansoprazole, rabeprazole, and pantoprazole.
Although the plasma half-life ($t_{1/2}$) of the parent molecules is relatively short (only 1.5–2 hours), the overall duration of action is significantly longer. It is limited by the rate of new enzyme biosynthesis in the body and lasts at least 18 hours, allowing patients to take the medication just once daily.
Special attention should be given to the treatment of peptic ulcer disease associated with Helicobacter pylori infection. Because this microorganism plays a key role in disease pathogenesis, PPI monotherapy is insufficient. PPIs must be combined with antibacterial agents, including amoxicillin, clarithromycin, and metronidazole.